Holen Sie sich die Stockscreener-App
69.12
1.65%
-1.16
Handel nachbörslich:
69.12
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BBIO (NASDAQ: BBIO) trust sells repeated 20,000-share blocks under 10b5-1 - Stock Titan
BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN
BridgeBio’s SWOT analysis: rare disease stock eyes profitability By Investing.com - Investing.com Canada
BridgeBio’s SWOT analysis: rare disease stock eyes profitability - Investing.com
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM) - The Globe and Mail
BBIO Initiates Coverage by Citigroup -- Rating Set to Neutral - GuruFocus
BBIO Stock Price Prediction 2025-2026 | BridgeBio Pharma Inc Forecast - 24/7 Wall St.
J.P. Morgan Initiates BridgeBio Pharma(BBIO.US) With Hold Rating, Announces Target Price $82 - Moomoo
Bridgebio Pharma Insider Sold Shares Worth $671,456, According to a Recent SEC Filing - Moomoo
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan
BridgeBio Pharma (BBIO) CEO reports RSU vesting and tax withholding share disposition - Stock Titan
BridgeBio (BBIO) CAO has 4,714 shares withheld at $66.13 for RSU taxes - Stock Titan
BridgeBio Pharma (BBIO) director exercises options and sells 10,000 shares - Stock Titan
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk - Yahoo Finance
BridgeBio falls despite new Attruby data - MSN
Citigroup initiates coverage of BridgeBio Pharma (BBIO) with neutral recommendation - MSN
[144] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a 55% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
VIRGINIA RETIREMENT SYSTEMS ET Al Increases Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Janus Henderson (BBIO) discloses 13,179,013 shares, 6.8% ownership - Stock Titan
How Encaleret’s NDA and New Acoramidis Milestones Could Reframe BridgeBio Pharma (BBIO) Investors’ Outlook - Yahoo Finance
BridgeBio (BBIO) Q1 2026 Earnings Transcript - AOL.com
BridgeBio Pharma stock (US10806X1028): Pipeline progress in rare diseases - AD HOC NEWS
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
BridgeBio outlines $500M share repurchase as it targets P&L breakeven in 2027 - MSN
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $101 - Moomoo
BridgeBio Files FDA NDA for Encaleret in ADH1 - TipRanks
BridgeBio (NASDAQ: BBIO) files NDA as encaleret hits Phase 3 goals in ADH1 - Stock Titan
Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO) - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches - MSN
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026Slideshow - Seeking Alpha
BridgeBio Oncology (NASDAQ: BBOT) ramps R&D and deepens Q1 2026 loss - Stock Titan
8 Most Promising Biotech Stocks to Buy Now - Insider Monkey
BridgeBio (BBIO) Positioned for Growth According to JPMorgan Ana - GuruFocus
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $102 to $157 - Moomoo
BridgeBio Submits NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1 - HCPLive
BridgeBio submits NDA for encaleret to treat rare genetic disorder By Investing.com - Investing.com Australia
HC Wainwright Issues Optimistic Outlook for BBIO Earnings - MarketBeat
Wall Street's Cardiac Bet: Where Diagnostics Meet the Money - Benzinga
BridgeBio submits NDA for encaleret to treat rare genetic disorder - Investing.com
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 - The Manila Times
BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial - Yahoo Finance
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival - BioSpace
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma(BBIO.US) Officer Sells US$5.39 Million in Common Stock - Moomoo
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat
BridgeBio Pharma (BBIO) Reports Promising Heart Failure Data Ami - GuruFocus
BridgeBio Pharma CEO Neil Kumar sells $5.39m in company stock - Investing.com Australia
BridgeBio Pharma CEO Neil Kumar sells $5.39m in company stock By Investing.com - Investing.com South Africa
BridgeBio Pharma (BBIO) Presents Promising Acoramidis Data at He - GuruFocus
Trusts tied to BridgeBio (NASDAQ: BBIO) CEO sell 80K company shares - Stock Titan
Trading the Move, Not the Narrative: (BBIO) Edition - Stock Traders Daily
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):